Siliq is an injectable drug intended to treat adults with moderate-to-severe plaque psoriasis, which causes patches of redness and flaking on the skin.
The drug’s label includes a boxed warning about the risk of suicide, as some patients treated with the drug during clinical trials demonstrated suicidal behavior, according to the FDA.
Valeant expects Siliq to hit the market in the second half of 2017.
More articles on supply chain:
Winter storms exacerbate blood shortage in New England
Price controversy threatens Marathon CEO’s seat on PhRMA board
7 must-reads for supply chain leaders this week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
